Completed PHASE2 INTERVENTIONAL 4-arm NCT00422461

A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF PF-00489791 IN SUBJECTS WITH STAGE 1 AND 2 ESSENTIAL HYPERTENSION USING AMBULATORY BLOOD PRESSURE MONITORING (ABPM)

Sponsor: Pfizer

Conditions Hypertension

Interventions PF-00489791 placebo

Updated 8 times since 2017 Last updated: Sep 13, 2021 Started: Feb 27, 2007 Primary completion: Jan 28, 2008 Completion: Jan 28, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hypertension, this trial is completed. The trial is conducted by Pfizer and has accumulated 8 data snapshots since 2007. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Nov 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Nov 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Brooklyn Center, United States , Cary, United States , Charlotte, United States , Cincinnati, United States , Farmington, United States , Jacksonville, United States , Knoxville, United States , Los Angeles, United States , Madisonville, United States , Nashville, United States and 8 more locations